engleski

In vivo efficacy testing of nanodrugs for Parkinson's disease treatment

The incidence of neurodegenerative diseases, including Parkinson’s disease (PD), is increasing with the aging of the population. PD is characterized by massive depletion of dopamine as a result of the degeneration of dopaminergic neurons, leading to motor symptoms and other neuropsychiatric and cognitive symptoms.1 Dopamine precursor levodopa (L-dopa) still represents the gold therapeutic standard for PD but long-term treatment can lead to serious side effects. Increased efficacy and better safety of PD treatment may be reached by novel formulation using nanotechnological tools and methods. Here, we present the design and efficacy of nanoformulation based on selenium nanoparticles (SeNPs), which exhibit antioxidant properties and neuroprotective effects.2 SeNPs stabilized with polyvinylpyrrolidone (PVP) were developed as a nanodelivery system for L-dopa. PVP-coated SeNPs were characterized by a hydrodynamic diameter of 82.9 ± 0.5 nm and a zeta potential of -28.0 ± 1.9 mV. The efficacy of such a system was tested using a hemiparkinsonian rat model, achieved by injection of 6-hydroxydopamine into the right hemisphere according to the stereotaxic atlas.3 Four weeks after injections, rats were treated orally with conventional L-dopa and L-dopa loaded on SeNPs for 28 days. Different behavioral assays were used to evaluate the efficacy of the treatments. The motor coordination was tested on the Rotarod apparatus, the neurological severity score (NSS) tests were used for estimating balance, motor coordination, and sensorimotor reflexes, while gait analysis was used to assess the changes in motor impairments in rats before and after surgery.4 Obtained results on improved motor dysfunction and coordination clearly showed beneficial effects of L-dopa loaded on SeNPs in comparison to L-dopa treatment.

Parkinson's disease, L-dopa, nanodrugs

nije evidentirano